ArticleHistochemistry and cell biology2025
ADAMTS-1, a multifunctional proteinase, in the uterus of both estrous cycle rats and ovariectomized rats can be regulated via hormones.
Article in Histochemistry and cell biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting ADAMTS1/HDAC6 alleviates TGF-β1/SMAD2-associated cardiac fibrosis in cardiac fibrosis post-myocardial infarction.Cell biology and toxicology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Remodeling of the extracellular matrix (ECM) throughout the estrous cycle is one of the most striking features of the uterus. A disintegrin and metalloprotease with thrombospondin type I motifs (ADAMTS-1) is a metalloproteinase responsible for the degradation of some proteoglycans, which are ECM components. In this study, ADAMTS-1 distribution was analyzed in the uterus of ovariectomized rats administered 17β-estradiol (E2) and progesterone (P4) and in the uterus at different estrous stages. Ovariectomized (OVX) rats were subjected to single and combined E2 (0.2 mg/kg) and P4 (10 mg/kg) hormone replacement therapies. E2 was administered for 3 consecutive days, followed by E2, P4, or E2 + P4 for 4 consecutive days. The serum level of E2 decreased from the proestrus phase to the diestrus phase, but that of P4 was the highest in the estrus phase. During the estrus phase, the serum level of luteinizing hormone (LH) was the lowest and that of follicle-stimulating hormone (FSH) was the highest. P4 level increased significantly in the OVX + P4 and OVX + E2 + P4 groups compared with the OVX group. The serum levels of LH and FSH decreased in the OVX + E2 and OVX + P4 groups compared with the OVX group, and were the lowest in the OVX + E2 + P4 group. ADAMTS-1 immunoreactivity in luminal, glandular, and stromal cells of the uterus decreased from proestrus to diestrus. When immunoreactivity in hormone replacement groups was compared, weak immunoreactivity was observed in the OVX group. ADAMTS-1 immunoreactivity gradually increased in OVX + P4 and OVX + E2 groups, and was particularly notable in luminal, glandular, and stromal cells in the OVX + E2 + P4 group. ADAMTS-1 distribution was affected by the estrous cycle process and hormone replacement therapy in the OVX procedure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.